Hematology/Oncology

Top Story

Intensification of rituximab fails to benefit untreated patients with CLL

September 1, 2015

Additional doses of rituximab did not improve responses rates among patients with chronic lymphocytic leukemia treated with the chemotherapy combination of fludarabine, cyclophosphamide and rituximab, according to results of a single-arm study.

Further, the intensification of rituximab (Rituxan; Genentech, Biogen Idec) increased the rate of secondary malignancies.

In the Journals

Recombinant FVIII with extended half life safe, effective for hemophilia A

September 1, 2015
BAX 855, a pegylated, full-length recombinant Factor VIII, appeared safe and effective for the biweekly prophylactic treatment of patients with hemophilia A, according…
Researchers find unsuspected DNA virus associated with HCC In the Journals

Researchers find unsuspected DNA virus associated with HCC

September 1, 2015
Adeno-associated virus type 2, a type of DNA virus, was associated with oncogenic insertional mutagenesis in human hepatocellular carcinoma cells, according to data…
FDA News

FDA grants priority review to elotuzumab for multiple myeloma

September 1, 2015
The FDA granted priority review to elotuzumab for the treatment of patients with multiple myeloma who have received at least one prior therapy, according to a press…
In the Journals

Nonmelanoma skin cancer in children, young adults associated with risk factors

September 1, 2015
Almost half of children and young adults with nonmelanoma skin cancer were exposed to risk factors, according to recently published study results.Researchers in Boston…
More News Headlines »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »